Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2020
    ABAliza B Solomon
    PMID: 32474949DOISenior author14 citations

Publications

23 publications

Clinical research

17 studies

Active

9 studies
  • PI
    A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease
    PHASE3 · Takeda Development Center Americas, Inc. · OPEN TO ACCRUAL (as of 2026)
    Ulcerative Colitis; Crohn's Disease
    NCT06405087
  • PI
    Evaluating Current Transition Practices and Needs in Pediatric and Adult Eosinophilic Esophagitis (EoE) Care: A National Provider Survey
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
  • PI
    A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care
    Regeneron Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2026)
    Eosinophilic Esophagitis (EoE)
    NCT06693531
  • PI
    A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 kg With Active Eosinophilic Esophagitis
    PHASE3 · Regeneron Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2026)
    Eosinophilic Esophagitis (EoE)
    NCT07112378
  • PI
    An Open-Label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
    PHASE3 · Takeda Development Center Americas, Inc. · OPEN TO ACCRUAL (as of 2025)
    Ulcerative Colitis; Crohn's Disease
    NCT06100289
  • PI
    A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease
    PHASE3 · Janssen Research & Development, LLC · OPEN TO ACCRUAL (as of 2024)
    Crohn's Disease
    NCT05923073
  • PI
    A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease
    PHASE3 · Eli Lilly and Company · OPEN TO ACCRUAL (as of 2024)
    Crohn's Disease
    NCT05509777
  • PI
    A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease
    PHASE3 · Janssen Research & Development, LLC · OPEN TO ACCRUAL (as of 2024)
    Crohn's Disease
    NCT05923073
  • PI
    Natural Disease Course and Vitamin Deficiencies in patients with Eosinophilic Esophagitis (EoE)
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2022)
Completed & closed trials (8)
  • PI
    A Single Center Analysis of Pre-Procedural Anxiety in Parents Before Pediatric GI Procedures as it Relates to Health Literacy and Language Barriers and the Impact of Pictures
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
  • PI
    Fecal Microbiota Transplant National Registry
    Department of Health & Human Services · IRB STUDY CLOSURE (as of 2024)
  • PI
    A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis
    PHASE3 · Regeneron Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2023)
    Eosinophilic Esophagitis (EoE)
    NCT04394351
  • PI
    A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis
    PHASE2; PHASE3 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2022)
    Ulcerative Colitis (UC)
    NCT03398148
  • PI
    PED-EoE-009
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
  • PI
    A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease
    PHASE3 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2021)
    Crohn's Disease
    NCT03105102
  • PI
    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Upadacitinib (ABT-494) for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
    PHASE2 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2021)
    Crohn's Disease
    NCT02365649
  • PI
    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
    PHASE3 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2021)
    Crohn's Disease
    NCT03345836